Hjem › Steatotisk leversygdom › Virginia
Steatotisk leversygdom kliniske forsøg i Virginia
14 studier for Steatotisk leversygdom søger deltagere på steder i Virginia.
Byer i Virginia
Officiel studietekst (engelsk)
Liver Cirrhosis Network Rosuvastatin Efficacy and Safety for Cirrhosis in the United States
- Virginia Commonwealth University, Richmond
RekruttererFase 2
Alder 18 til 75 · Alle køn · Opdateret 28. sep. 2026 · NCT05832229A Precision Medicine Approach Using Gene Silencing to Treat a Chronic Liver Disease Called Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Adult Participants at Increased Genetic Risk for This Condition
- University of Virginia Medical Center, Charlottesville
- Richmond Veterans Administration Medical Center, Richmond
RekruttererFase 2
Alder 18 til 75 · Alle køn · Opdateret 25. sep. 2026 · NCT05519475A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)
- Eximia Research - Norfolk, Norfolk
- Richmond Veterans Affairs Medical Center (Richmond VA Medical Center), Richmond
- Virginia Commonwealth University (VCU) Medical Center, Richmond
- og 1 flere
RekruttererFase 3
Alder 18 og opefter · Alle køn · Opdateret 22. sep. 2026 · NCT07165028A Study Evaluating Efruxifermin in Subjects With Compensated Cirrhosis Due to NASH/MASH
- Akero Clinical Study Site, Norfolk
- Akero Clinical Study Site, Richmond
- Akero Clinical Study Site, Richmond
- og 3 flere
RekruttererFase 3
Alder 18 til 80 · Alle køn · Opdateret 21. sep. 2026 · NCT06528314A Clinical Study to Investigate the Safety and Tolerability of Efimosfermin Alfa Injection in Participants With Known or Suspected F2- or F3-stage MASH
- GSK Investigational Site, Manassas
RekruttererFase 3
Alder 18 til 75 · Alle køn · Opdateret 17. sep. 2026 · NCT07221188A Study of a Thyroid Hormone Receptor Beta Isoform (THRβ) Agonist and an Semicarbazide Sensitive Amine Oxidase (SSAO) Inhibitor, Alone and in Combination, in Adults With Presumed Metabolic Dysfunction-associated Steatohepatitis (MASH)
- GI Alliance Richmond, Richmond
- GI Select Health Research, Richmond
RekruttererFase 2
Alder 18 til 75 · Alle køn · Opdateret 9. sep. 2026 · NCT07288138A Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With MASH and Fibrosis (ENLIGHTEN-Fibrosis)
- 89bio Clinical Study Site, Richmond
- 89bio Clinical Study Site, Richmond
- 89bio Clinical Study Site, Richmond
- og 1 flere
RekruttererFase 3
Alder 18 til 80 · Alle køn · Opdateret 3. sep. 2026 · NCT06318169A Study to Evaluate the Efficacy and Safety of Pegozafermin in Participants With Compensated Cirrhosis Due to MASH
- 89bio Clinical Study Site, Richmond
- 89bio Clinical Study Site, Richmond
- 89bio Clinical Study Site, Richmond
RekruttererFase 3
Alder 18 til 75 · Alle køn · Opdateret 3. sep. 2026 · NCT06419374A Study to Investigate the Safety and Efficacy of GSK4532990 Compared With Placebo in Adult Participants Aged 18 to 70 Years With Alcohol-related Liver Disease
- GSK Investigational Site, Richmond
- GSK Investigational Site, Richmond
RekruttererFase 2
Alder 18 til 70 · Alle køn · Opdateret 3. aug. 2026 · NCT06613698A Pivotal Clinical Study to Investigate Efimosfermin Alfa in Participants With Biopsy-confirmed F2- or F3-stage MASH
- GSK Investigational Site, Manassas
- GSK Investigational Site, Norfolk
RekruttererFase 3
Alder 18 til 75 · Alle køn · Opdateret 27. jul. 2026 · NCT07221227A Study of Efimosfermin Alfa in Participants With Biopsy-confirmed Cirrhosis (Compensated) Due to MASH
- GSK Investigational Site, Richmond
RekruttererFase 2
Alder 18 til 75 · Alle køn · Opdateret 8. jul. 2026 · NCT06920043Randomized Double Blinded Placebo-Controlled w/Semaglutide to Prevent Weight Gain After Liver Transplant
- Virginia Commonwealth University, Richmond
RekruttererFase 2
Alder 18 til 75 · Alle køn · Opdateret 4. jun. 2026 · NCT05424003Non-Invasive Quantification of Liver Health in NASH (N-QUAN)
- University of Virginia, Charlottesville
- Virginia Common wealth University, Richmond
Rekrutterer
Alder 18 til 75 · Alle køn · Opdateret 19. maj 2026 · NCT04054310Predicting Outcomes in Nonalcoholic Steatohepatitis With Advanced Fibrosis
- Virginia Commonwealth University, Richmond
RekruttererObservationsstudie
Alder 18 og opefter · Alle køn · Opdateret 2. apr. 2026 · NCT05720663Fra ClinicalTrials.gov, data hentet 5. okt. 2026. Hver studie har sine egne kvalifikationskrav; studieteamet afgør, hvem der kan deltage.